MDS Nordion (ticker: MDS.TO, exchange: Toronto Stock Exchange (.TO)) News Release - 2/7/2005
MDS Pharma Services to Host Symposium on Effective Solutions for Pharmaceutical Development Challenges
MONTREAL--(BUSINESS WIRE)--Feb. 7, 2005--MDS Pharma Services, a leading provider of innovative drug discovery and development solutions and an integral part of MDS Inc. (TSX:MDS) (NYSE:MDZ), will host a pharmaceutics-focused Scientific Leadership Series symposium on February 23-24 in Tampa, Florida. Leading researchers from industry and academia will address the scientific and regulatory challenges associated with speed to first-in-man studies for new chemical entities and life-cycle management for existing branded compounds.
Topics and speakers for this two-day event will include:
-- "Physicochemical Properties of Drug Molecules and Their
Influence on Formulation Design and Performance," Dr. Gordon
Flynn, University of Michigan;
-- "Developing Dissolution Methods for Poorly Soluble Actives -
Techniques and Case Studies," Vivian Gray, V.A. Gray
Consulting Inc.;
-- "Lipid-Based Delivery Systems for Enhanced Exposure: What are
the Opportunities and are They Predictable?" Dr. Christopher
Porter, Monash University;
-- "Hard Gelatin Capsules and Their Use in Toxicity Studies," Dr.
Carey Bottom, Shionogi Qualicaps;
-- "The Challenge of Chirality in Drug Development," Dr. Joseph
Gal, University of Colorado School of Medicine;
-- "Expedited Early Phase Development Strategies for an Immediate
Release Capsule Dosage Form," Paul Stach, MDS Pharma Services;
-- "Accelerating Drug Development with Precision Dosing
Techniques," David Edwards, Meridica-Pfizer;
-- "Virtual Drug Development - Keys to Managing Successful
Third-Party Relationships," Kevin Sills, King Pharmaceuticals;
-- "The Development Challenges of Natural Products as
Pharmaceuticals," Dr. James McChesney, Tapestry
Pharmaceuticals; and
-- "Regulatory Strategies for Product Life Cycle Management," Dr.
Robert Butz, MDS Pharma Services.
Workshops on "Polymorphism in Drug Product Development," and "Chirality in Drug Development," along with an interactive session regarding "Strategies for Expedited Early Phase Development," will be facilitated. Individuals interested in attending this free Scientific Leadership Series symposium are encouraged to register online at www.mdsps.com/events/Tampa2004.htm or via e-mail at pharmaceutics.symposium@mdsps.com. MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process - early stage: lead optimization, pre-IND research, pharmaceutical and biopharmaceutical development, early clinical research (bioequivalence, phases I-IIa) and bioanalysis; and late stage: global clinical development (phases IIb-IV) and central lab. For more information, visit MDS Pharma Services' Web site at www.mdsps.com. MDS Pharma Services is an integral part of MDS Inc. (TSX:MDS)(NYSE:MDZ). MDS Inc. has more than 9,000 highly skilled people in 25 countries providing a diverse range of superior products and services to increase our customers' speed, precision and productivity in the drug development and disease diagnosis processes. We are a global health and life sciences company, recognized for our reliability and collaborative relationships. Please refer to our website at www.mdsintl.com to find out more about how we help create better outcomes in the treatment of disease.
CONTACT: MDS Pharma Services
Kim Peacock, 402-476-2811
www.mdsps.com
SOURCE: MDS Pharma Services
|